Tharimmune, Inc.
Nir Barak serves as the Chief Medical Advisor at Tharimmune, Inc. since October 2023, contributing to the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. In addition, Nir Barak is the Founder of RNR BioMedical Inc., which focuses on patient-centered treatments for rare diseases through innovative drug repurposing strategies. Previously, Nir Barak held the position of Senior VP of Scientific Affairs at 9 Meters Biopharma, Inc. and served as Chief Medical Officer and CEO at RDD Pharma Ltd. Nir Barak's earlier roles include Chief Scientific Officer at Obecure and Attending Physician at Beilinson Hospital. Educational qualifications include a Doctor of Medicine (MD) from Tel Aviv University, Board Certification in Internal Medicine from Sapir Medical Center, and certification as a Clinical Nutrition Support Physician from the University of Chicago.
This person is not in any teams
Tharimmune, Inc.
Tharimmune, Inc. (Nasdaq: THAR) is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against specified targets. For more information please visit: www.tharimmune.com